Loss of patents of some key drugs in multinational pharma has enabled Indian pharma companies to have higher growth rates in chronic and sub-chronic therapy segments, according to data from market research firm PharmaTrac. Several cardiac and diabetes drugs went off patent in recent years such as Vildagliptin or Sacubitril-Valsartan. Several Indian companies launched generic versions of these drugs soon after that. However, smaller corporates are losing out.
![chart chart](https://bsmedia.business-standard.com/_media/bs/img/article/2023-12/08/full/1701974303-4781.jpg)
First Published: Dec 08 2023 | 12:11 PM IST